OncRef

Clinical Trial: NCT03239340

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2024-10-21

Study Overview

Brief Summary

A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.

Official Title

A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Conditions

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Osimertinib

Other Study ID Numbers

  • D5161C00003
  • 2017-002359-27
  • 2017

Start Date (Actual)

2018-05-30

Primary Completion Date (Actual)

2023-09-19

Study Completion Date (Actual)

2023-09-19

Enrollment (Actual)

154

Study Type

Interventional

Phase

Phase 2